-+ 0.00%
-+ 0.00%
-+ 0.00%

Korro Bio selects KRRO-111 RNA-editing candidate for alpha-1 antitrypsin deficiency

PUBT·05/19/2026 11:03:09
Listen to the news
Korro Bio selects KRRO-111 RNA-editing candidate for alpha-1 antitrypsin deficiency
  • Korro Bio selected KRRO-111 as a development candidate for alpha-1 antitrypsin deficiency, positioning it as a potential subcutaneous genetic medicine aimed at addressing the underlying cause of disease in the liver and lungs.
  • Preclinical studies showed broad correction of the disease-driving RNA change, restoring production of functional protein while sharply reducing the harmful variant linked to liver injury.
  • Repeat dosing supported the potential for durable, controllable treatment effects without making permanent changes to the genome.
  • Additional KRRO-111 data will be presented at a future scientific meeting or a company-hosted event.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190700PRIMZONEFULLFEED9722710) on May 19, 2026, and is solely responsible for the information contained therein.